Evidence map›Paper›PMID 36075089›Full record

ArticleArchivos de cardiologia de Mexico2022

Should a recent SARS-CoV-2 infection be considered a risk or prognostic factor for ST-segment elevation myocardial infarction?

Kietseé A Díaz-Domínguez, Andrés Cruz-Melendez, Luis M Amezcua-Castillo, Jazmin A Guerra-López, Claudia Tavera-Alonso, Héctor González-Pacheco, Luis M Amezcua-Guerra

Open access · diamondAbstract read
In one paragraph

Article in Archivos de cardiologia de Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. The impact of COVID-19 and COVID vaccination on cardiovascular outcomes.European heart journal supplements : journal of the European Society of Cardiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Kietseé A Díaz-DomínguezDepartment of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Andrés Cruz-MelendezCore Lab, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Luis M Amezcua-CastilloCoronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Jazmin A Guerra-LópezDepartment of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Claudia Tavera-AlonsoCore Lab, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Héctor González-PachecoCoronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Luis M Amezcua-GuerraDepartment of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Instituto Nacional de Cardiologia · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The aim of the study was to assess whether a recent SARS-CoV-2 infection could by itself be a risk or prognostic factor for ST-segment elevation myocardial infarction (STEMI). Method: An observational study in unvaccinated patients with STEMI confirmed by cardiac catheterization was conducted. A recent or concurrent SARS-CoV-2 infection was identified by the presence of serum IgG against the nucleocapsid protein, or a positive polymerase chain reaction test on nasopharyngeal swabs. Baseline cardiovascular risk factors, clinical STEMI severity, main catheterization findings, and occurrence of major adverse cardiovascular events (MACE) during hospitalization were compared between study subgroups. Results: Of a total of 89 patients recruited, 14 (16%) had a recent SARS-CoV-2 infection. Patients with STEMI and recent SARS-CoV-2 infection had a markedly lower frequency of high blood pressure (20% versus 55%; P = 0.03) as well as a tendency to have fewer comorbidities. Regarding the clinical presentation, there were no differences in the severity of the STEMI. Furthermore, the main findings during cardiac catheterization including the atherosclerotic burden and the number of vessels affected, as well as the occurrence of MACE during follow-up, were not significantly different between the groups. Conclusions: A recent SARS-CoV-2 infection appears to facilitate the triggering of STEMI, as these patients have fewer traditional cardiovascular risk factors than their uninfected counterparts. However, this does not seem to affect the clinical presentation or the in-hospital course of STEMI patients.

Indexed as

Acute coronary syndromeCoronavirus disease 2019SARS-CoV-2ST-segment elevation myocardial infarction

Identifiers

PMID36075089
PMCPMC12169362
OpenAlexW4294970296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.